Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Deviations From Clinical Trials Registration in the ED-SAFE Study—Reply

Deviations From Clinical Trials Registration in the ED-SAFE Study—Reply Letters COMMENT & RESPONSE information to draw conclusions about the utility of the tested intervention. In Reply We appreciate the opportunity to respond to Amos’ Furthermore, it is our opinion that regardless of the spe- comments about our study. Amos raised questions about the cific comparisons, data analyses, or P values, the overall pat- association between our study and the information con- tern of results as reported in our study is consistent and quite tained in the clinical trials registration. Although we agree with clear. Across multiple variables, comparisons, and analyses, Amos’ concern about the congruence of clinical trial registra- participants in the treatment as usual and screening phases had tion and publications, we take issue with several of the points very similar frequencies of subsequent suicidal behavior. Rela- he raised about our study. First, contrary to Amos’ com- tive to participants in these phases, participants in the inter- ments, we did report deaths by suicide separately in the Out- vention phase have a clinically significant reduction in future comes subsection of the study. Second, nowhere in our study suicidal behaviors. do we “claim that the study contributes to evidence that lives can be saved.” In fact, we explicitly http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Psychiatry American Medical Association

Deviations From Clinical Trials Registration in the ED-SAFE Study—Reply

Download PDF
1 page

Deviations From Clinical Trials Registration in the ED-SAFE Study—Reply

Abstract

Letters COMMENT & RESPONSE information to draw conclusions about the utility of the tested intervention. In Reply We appreciate the opportunity to respond to Amos’ Furthermore, it is our opinion that regardless of the spe- comments about our study. Amos raised questions about the cific comparisons, data analyses, or P values, the overall pat- association between our study and the information con- tern of results as reported in our study is consistent and quite tained in the clinical...
Loading next page...
 
/lp/american-medical-association/deviations-from-clinical-trials-registration-in-the-ed-safe-study-6XatGiLSDm

References (2)

Publisher
American Medical Association
Copyright
Copyright 2017 American Medical Association. All Rights Reserved.
ISSN
2168-622X
eISSN
2168-6238
DOI
10.1001/jamapsychiatry.2017.2487
Publisher site
See Article on Publisher Site

Abstract

Letters COMMENT & RESPONSE information to draw conclusions about the utility of the tested intervention. In Reply We appreciate the opportunity to respond to Amos’ Furthermore, it is our opinion that regardless of the spe- comments about our study. Amos raised questions about the cific comparisons, data analyses, or P values, the overall pat- association between our study and the information con- tern of results as reported in our study is consistent and quite tained in the clinical trials registration. Although we agree with clear. Across multiple variables, comparisons, and analyses, Amos’ concern about the congruence of clinical trial registra- participants in the treatment as usual and screening phases had tion and publications, we take issue with several of the points very similar frequencies of subsequent suicidal behavior. Rela- he raised about our study. First, contrary to Amos’ com- tive to participants in these phases, participants in the inter- ments, we did report deaths by suicide separately in the Out- vention phase have a clinically significant reduction in future comes subsection of the study. Second, nowhere in our study suicidal behaviors. do we “claim that the study contributes to evidence that lives can be saved.” In fact, we explicitly

Journal

JAMA Psychiatry – American Medical Association

Published: Dec 4, 2017

There are no references for this article.